EP0785786A4 - Synthese microbienne d'inhibiteurs de la protease du vih - Google Patents

Synthese microbienne d'inhibiteurs de la protease du vih

Info

Publication number
EP0785786A4
EP0785786A4 EP95937602A EP95937602A EP0785786A4 EP 0785786 A4 EP0785786 A4 EP 0785786A4 EP 95937602 A EP95937602 A EP 95937602A EP 95937602 A EP95937602 A EP 95937602A EP 0785786 A4 EP0785786 A4 EP 0785786A4
Authority
EP
European Patent Office
Prior art keywords
protease inhibitors
hiv protease
microbial synthesis
microbial
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95937602A
Other languages
German (de)
English (en)
Other versions
EP0785786A1 (fr
Inventor
Ali Shafiee
Shieh-Shung T Chen
Byron H Arison
Randall R Miller
George M Garrity
Brian Heimbuch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0785786A1 publication Critical patent/EP0785786A1/fr
Publication of EP0785786A4 publication Critical patent/EP0785786A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
EP95937602A 1994-10-25 1995-10-20 Synthese microbienne d'inhibiteurs de la protease du vih Withdrawn EP0785786A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32863494A 1994-10-25 1994-10-25
US328634 1994-10-25
PCT/US1995/013628 WO1996012492A1 (fr) 1994-10-25 1995-10-20 Synthese microbienne d'inhibiteurs de la protease du vih

Publications (2)

Publication Number Publication Date
EP0785786A1 EP0785786A1 (fr) 1997-07-30
EP0785786A4 true EP0785786A4 (fr) 1998-01-28

Family

ID=23281761

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95937602A Withdrawn EP0785786A4 (fr) 1994-10-25 1995-10-20 Synthese microbienne d'inhibiteurs de la protease du vih

Country Status (4)

Country Link
EP (1) EP0785786A4 (fr)
JP (1) JPH10507917A (fr)
AU (1) AU702122B2 (fr)
WO (1) WO1996012492A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612217A (en) * 1994-10-25 1997-03-18 Merck & Co., Inc. Streptomyces sp. MA 7074 (ATCC 55605) used for microbial synthesis of HIV protease inhibitors
US5976857A (en) * 1996-01-26 1999-11-02 Boehringer Mannheim Corporation Cross-linked polypeptide fragments of β-galactosidase
DE69709448T2 (de) * 1996-01-26 2002-09-19 Roche Diagnostics Corp Bismaleinsäureimid-vernetzer
US5763196A (en) * 1996-01-26 1998-06-09 Boehringer Mannheim Corporation Assays using cross-linked polypeptide fragments of β-galactosidase
WO2004022548A1 (fr) * 2002-09-05 2004-03-18 Toray Fine Chemicals Co,. Ltd. Procede de production de derive piperazine a substitution oxycarbonyle
JP2004115510A (ja) * 2002-09-05 2004-04-15 Toray Fine Chemicals Co Ltd ピペラジン誘導体の製造方法
CN101497608B (zh) * 2009-03-05 2011-11-09 中国科学院广州生物医药与健康研究院 一类hiv蛋白酶抑制剂衍生物及其制备方法和在制备抗肿瘤药中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012790A1 (fr) * 1994-10-25 1996-05-02 Merck & Co., Inc. Synthese microbienne d'inhibiteurs de protease de hiv

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3160560A (en) * 1957-08-23 1964-12-08 Upjohn Co Streptolydigin and production thereof
JPS5774090A (en) * 1980-10-27 1982-05-10 Shionogi & Co Ltd Novel beta-galactosidase inhibitor, gt-2558, its derivative, and production
EP0541168B1 (fr) * 1991-11-08 1998-03-11 Merck & Co. Inc. Inhibiteurs d'HIV-protéase utilisables dans le traitement du SIDA
CA2110827A1 (fr) * 1992-12-14 1994-06-15 Maki Nishio Antibiotique antiviral bu-4724v et preparation en contenant
SI9420017B (sl) * 1993-03-31 2003-12-31 Merck & Co. Inc. Inhibitorji proteaze hiv-a v farmacevtskih kombinacijah za zdravljenje aids-a

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012790A1 (fr) * 1994-10-25 1996-05-02 Merck & Co., Inc. Synthese microbienne d'inhibiteurs de protease de hiv

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9612492A1 *

Also Published As

Publication number Publication date
AU3966395A (en) 1996-05-15
EP0785786A1 (fr) 1997-07-30
JPH10507917A (ja) 1998-08-04
AU702122B2 (en) 1999-02-11
WO1996012492A1 (fr) 1996-05-02

Similar Documents

Publication Publication Date Title
PL313871A1 (en) Inhibitors of hiv protease
PL314838A1 (en) Inhibitors of bp-iv-serine protease
PL322877A1 (en) Sulphonamidic inhibitors of aspartil hiv protease containing thf
AP9701054A0 (en) Inhibitors of cycteine protease
PL323710A1 (en) Reversible inhibitors of cysteinic protease
PL326508A1 (en) Protease inhibitors
IL118101A0 (en) Inhibitors of farnesyltransferase
AU1271297A (en) Inhibitor of ceramidase
AU3868095A (en) Apolipoprotein-b synthesis inhibitors
PL328665A1 (en) Inhibitors of serinic protease
PL337725A1 (en) Inhibitors of proteases
PL319905A1 (en) Apolipoprotein b synthesis inhibitors
PL314486A1 (en) Precursors of hiv protease inhibitors
AU2251892A (en) Inhibitors of picornavirus proteases
EP0691345A3 (fr) Combinaisons d'inhibiteurs de la protéase d'HIV
HUP9802764A3 (en) Guanidino protease inhibitors
AU7523194A (en) Tick derived protease inhibitor
AUPM982594A0 (en) HIV protease inhibitors
EP0785786A4 (fr) Synthese microbienne d'inhibiteurs de la protease du vih
GB9515802D0 (en) Hiv protease inhibitors useful for the treatment of aids
HUP0105439A3 (en) Process for the synthesis of hiv protease inhibitors
EP0785989A4 (fr) Synthese microbienne d'inhibiteurs de protease de hiv
AU8159594A (en) Novel inhibitor
HU0900220D0 (en) Hiv protease inhibitors
SI0746320T1 (en) Hiv protease inhibitors and intermediates

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970526

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

RHK1 Main classification (correction)

Ipc: C07D401/06

A4 Supplementary search report drawn up and despatched

Effective date: 19971215

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19981210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020501